troglitazone has been researched along with Hypertriglyceridemia in 9 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Hypertriglyceridemia: A condition of elevated levels of TRIGLYCERIDES in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the effects of troglitazone (TRO)--a new insulin-sensitizing agent--on some metabolic parameters in an experimental model of hypertriglyceridemia and insulin resistance, hereditary hypertriglyceridemic rats, and to compare its effects with those of vitamin E, an antioxidant agent." | 7.71 | A comparison of the effects of troglitazone and vitamin E on the fatty acid composition of serum phospholipids in an experimental model of insulin resistance. ( Chvojková, S; Divisová, J; Kazdová, L, 2001) |
| "The aim of this study was to investigate the effects of troglitazone (TRO)--a new insulin-sensitizing agent--on some metabolic parameters in an experimental model of hypertriglyceridemia and insulin resistance, hereditary hypertriglyceridemic rats, and to compare its effects with those of vitamin E, an antioxidant agent." | 3.71 | A comparison of the effects of troglitazone and vitamin E on the fatty acid composition of serum phospholipids in an experimental model of insulin resistance. ( Chvojková, S; Divisová, J; Kazdová, L, 2001) |
| "Troglitazone is a valuable addition to the arsenal of antidiabetic drugs for type 2 diabetes." | 2.40 | Troglitazone. Is it all over? ( Hoekstra, JB; Kuck, EM; Wagenaar, LJ, 1999) |
| "In conclusion, improvement of hyperinsulinemia can decrease NHE activity and blood pressure in fructose-fed BHR." | 1.32 | Troglitazone reduces activity of the Na+/H+ exchanger in fructose-fed borderline hypertensive rats. ( Fujioka, Y; Iwasaki, T; Masai, M; Morimoto, S; Ohyanagi, M; Okumura, T; Tsuboi, S; Tsujino, T, 2003) |
| "Dyslipoproteinemia associated with type 2 diabetes comprises hypertriglyceridemia caused by reduced insulin sensitivity, and consequently, low HDL levels and an increase in the proportion of small dense LDL particles." | 1.31 | [Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects]. ( Demant, T, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, J | 1 |
| Bailey, P | 1 |
| Biswas, C | 1 |
| Cullinan, CA | 1 |
| Doebber, TW | 1 |
| Hayes, NS | 1 |
| Saperstein, R | 1 |
| Smith, RG | 1 |
| Leibowitz, MD | 1 |
| Fujioka, Y | 1 |
| Masai, M | 1 |
| Tsuboi, S | 1 |
| Okumura, T | 1 |
| Morimoto, S | 1 |
| Tsujino, T | 1 |
| Ohyanagi, M | 1 |
| Iwasaki, T | 1 |
| Shibata, T | 1 |
| Matsui, K | 1 |
| Nagao, K | 1 |
| Shinkai, H | 1 |
| Yonemori, F | 1 |
| Wakitani, K | 1 |
| Wagenaar, LJ | 1 |
| Kuck, EM | 1 |
| Hoekstra, JB | 1 |
| Chicco, A | 1 |
| Basabe, JC | 1 |
| Karabatas, L | 1 |
| Ferraris, N | 1 |
| Fortino, A | 1 |
| Lombardo, YB | 1 |
| McCarthy, KJ | 1 |
| Routh, RE | 1 |
| Shaw, W | 1 |
| Walsh, K | 1 |
| Welbourne, TC | 1 |
| Johnson, JH | 1 |
| Harano, Y | 1 |
| Chvojková, S | 1 |
| Kazdová, L | 1 |
| Divisová, J | 1 |
| Demant, T | 1 |
2 reviews available for troglitazone and Hypertriglyceridemia
| Article | Year |
|---|---|
Troglitazone. Is it all over?
Topics: Animals; Blood Glucose; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; | 1999 |
[Lipodystrophia].
Topics: Animals; Cardiomyopathy, Hypertrophic; Chromans; Diabetes Mellitus; Diagnosis, Differential; Fatty L | 2001 |
7 other studies available for troglitazone and Hypertriglyceridemia
| Article | Year |
|---|---|
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.
Topics: Animals; Blood Glucose; COS Cells; Cricetinae; Diabetes Mellitus; Hyperglycemia; Hypertriglyceridemi | 1996 |
Troglitazone reduces activity of the Na+/H+ exchanger in fructose-fed borderline hypertensive rats.
Topics: Animals; Bezafibrate; Blood Glucose; Blood Platelets; Blood Pressure; Calcium; Chromans; Diet; Eicos | 2003 |
Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
Topics: 3T3 Cells; Administration, Oral; Animals; Blood Glucose; Cell Differentiation; Chromans; Diabetes Me | 1999 |
Troglitazone (CS-045) normalizes hypertriglyceridemia and restores the altered patterns of glucose-stimulated insulin secretion in dyslipidemic rats.
Topics: Animals; Body Weight; Chromans; Dietary Sucrose; Fatty Acids, Nonesterified; Glucose; Hypertriglycer | 2000 |
Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion.
Topics: Animals; Basement Membrane; Body Weight; Chondroitin Sulfate Proteoglycans; Chromans; Diabetes Melli | 2000 |
A comparison of the effects of troglitazone and vitamin E on the fatty acid composition of serum phospholipids in an experimental model of insulin resistance.
Topics: Animals; Antioxidants; Blood Glucose; Blood Pressure; Chromans; Disease Models, Animal; Fatty Acids; | 2001 |
[Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects].
Topics: Anticholesteremic Agents; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Chromans; Clinical Tria | 2001 |